Anti dyslipedemic drugs

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

I've used my DB query budget. I have enough from the library and my own pharmacology knowledge to give a comprehensive answer. Let me also quickly check for the Fuster & Hurst lipid therapy section and Fitzpatrick PCSK9 content that appeared in earlier results, and compile the full answer now.

Based on all the library findings and my clinical pharmacology knowledge, here is a comprehensive overview of antidyslipidemic drugs:

Antidyslipidemic Drugs

Dyslipidemia refers to abnormal levels of lipids in the blood - elevated LDL-C, elevated triglycerides (TG), reduced HDL-C, or combinations thereof. Drug therapy targets these abnormalities through several distinct mechanisms.

1. HMG-CoA Reductase Inhibitors (Statins)

Drugs: Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Pitavastatin

Mechanism of Action:

Inhibit 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis (conversion of HMG-CoA to mevalonic acid)
Reduced intrahepatic cholesterol -> upregulation of LDL receptors on hepatocytes -> increased LDL-C clearance from plasma
Inhibit synthesis of isoprenoids (mevalonate pathway intermediates) - this underlies the pleiotropic anti-inflammatory effects

Lipid Effects:

LDL-C: reduce by 18-55%
TG: reduce by 7-30%
HDL-C: modest increase (5-15%)

Statin Intensity (ACC/AHA classification):

Intensity	Drug & Dose	LDL Reduction
High	Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg	≥50%
Moderate	Atorvastatin 10-20 mg, Simvastatin 20-40 mg, Pravastatin 40-80 mg	30-49%
Low	Simvastatin 10 mg, Pravastatin 10-20 mg	<30%

Adverse Effects:

Myopathy / rhabdomyolysis (risk ↑ with high dose, CYP3A4 interactions)
Elevated transaminases (hepatotoxicity - rare)
New-onset type 2 diabetes (modest risk)
Contraindicated in pregnancy

Key clinical notes: Statin therapy is the first-line drug for most patients with elevated LDL-C and for cardiovascular risk reduction. In PAD patients, moderate-intensity statin is recommended irrespective of baseline LDL. Simvastatin reduced vascular mortality by 17% in the Heart Protection Study.

Fuster and Hurst's The Heart, 15th Edition

2. Cholesterol Absorption Inhibitors

Drug: Ezetimibe

Mechanism:

Inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the brush border of small intestinal enterocytes
Blocks absorption of dietary and biliary cholesterol
Reduced cholesterol delivery to liver -> upregulation of hepatic LDL receptors
Additive effect when combined with statins

Lipid Effects:

LDL-C: reduces by ~18-20% (additional 15-20% on top of statin)
TG: modest reduction
HDL-C: modest increase

Adverse Effects: Generally well tolerated; rare myopathy (especially if combined with statin); diarrhea

Clinical use: Second-line add-on to statin in high-risk patients not reaching LDL goal (e.g., post-ACS, familial hypercholesterolemia).

3. PCSK9 Inhibitors

Drugs: Evolocumab (Repatha), Alirocumab (Praluent) - monoclonal antibodies; Inclisiran (siRNA)

Mechanism:

Proprotein convertase subtilisin/kexin type 9 (PCSK9) normally binds to LDL receptors on hepatocytes and targets them for lysosomal degradation
These antibodies block PCSK9, preventing LDL receptor degradation -> more LDL receptors available on hepatocyte surface -> marked increase in LDL-C clearance
Inclisiran uses RNA interference to silence PCSK9 gene expression in hepatocytes (given twice yearly subcutaneously)

Lipid Effects:

LDL-C: reduce by 50-60% on top of statin (+ezetimibe)
When given without statin: LDL reductions >60%

Clinical Trial Evidence:

FOURIER trial (evolocumab): Significantly reduced cardiovascular death, MI, stroke, and major adverse limb events in PAD patients; absolute risk reduction was greater in PAD (3.5%) vs non-PAD (1.6%)
ODYSSEY trial (alirocumab): Reduced events in patients with recent ACS and suboptimal LDL despite maximum statin

Adverse Effects: Injection site reactions; rare neurocognitive effects (not conclusively proven); expensive

Indications: Familial hypercholesterolemia; high CVD risk patients not achieving LDL goals on maximum statin + ezetimibe

Fitzpatrick's Dermatology 5e; Fuster and Hurst's The Heart, 15th Edition; Bradley and Daroff's Neurology in Clinical Practice

4. Bile Acid Sequestrants (Resins)

Drugs: Cholestyramine, Colestipol, Colesevelam

Mechanism:

Bind bile acids in the intestinal lumen, preventing enterohepatic recirculation
Reduced hepatic bile acid return -> hepatocytes divert cholesterol to synthesize new bile acids -> reduced intracellular cholesterol -> upregulation of LDL receptors -> increased LDL-C clearance from plasma
Act entirely in the gut (not systemically absorbed - safest option in pregnancy considerations)

Lipid Effects:

LDL-C: reduce by 15-30%
TG: can INCREASE (use cautiously in hypertriglyceridemia)
HDL-C: modest increase

Adverse Effects: GI side effects (bloating, constipation, flatulence); impair absorption of fat-soluble vitamins (A, D, E, K) and many drugs (take 1 hour before or 4-6 hours after other meds); bad taste (cholestyramine powder)

Special note: Colesevelam also approved for glycemic control in type 2 diabetes.

5. Fibrates (Fibric Acid Derivatives)

Drugs: Fenofibrate, Gemfibrozil, Bezafibrate, Ciprofibrate

Mechanism:

Activate peroxisome proliferator-activated receptor alpha (PPAR-α) in liver and muscle
PPAR-α activation:
- Increases lipoprotein lipase (LPL) activity -> enhanced TG-rich lipoprotein clearance
- Reduces apolipoprotein C-III (an LPL inhibitor)
- Increases apo A-I and A-II synthesis -> raises HDL-C
- Increases hepatic fatty acid oxidation -> reduces TG synthesis

Lipid Effects:

TG: reduce by 35-50% (main effect)
HDL-C: increase by 10-20%
LDL-C: variable (can increase in severe hypertriglyceridemia)

Adverse Effects:

Myopathy (risk ↑ with concomitant statins - gemfibrozil > fenofibrate)
Cholelithiasis (increased biliary cholesterol secretion)
Hepatotoxicity (mild transaminase elevation)
Renal: increased creatinine (fenofibrate)

Preferred use: Severe hypertriglyceridemia (TG >500 mg/dL, to prevent pancreatitis); combined dyslipidemia with low HDL. Fenofibrate preferred over gemfibrozil when combining with a statin.

6. Niacin (Nicotinic Acid)

Drug: Immediate-release niacin, Extended-release niacin (Niaspan)

Mechanism:

Inhibits adipose tissue lipolysis (via G-protein coupled receptor GPR109A) -> reduces flux of free fatty acids to liver -> reduced hepatic TG and VLDL synthesis
Reduces VLDL secretion and hence LDL-C production
Reduces HDL-C catabolism (reduces hepatic uptake of HDL-C)

Lipid Effects:

HDL-C: increases by 15-35% (most potent HDL raiser available)
TG: reduces by 20-50%
LDL-C: reduces by 15-25%

Adverse Effects:

Flushing (prostaglandin-mediated; reduced by aspirin pretreatment or extended-release formulation)
Hyperglycemia / worsening insulin resistance
Hyperuricemia / gout precipitation
Hepatotoxicity (especially sustained-release)
Peptic ulcer disease

Note: Despite favorable lipid effects, clinical trials (AIM-HIGH, HPS2-THRIVE) showed no cardiovascular benefit of adding niacin to statin therapy; use has markedly declined.

7. Omega-3 Fatty Acids

Drugs: Icosapentaenoic acid (EPA) - Vascepa (icosapent ethyl); EPA + DHA - Lovaza, Epanova

Mechanism:

Reduce hepatic TG synthesis
Enhance TG clearance via LPL activation
At high doses (4 g/day), reduce VLDL-TG production

Lipid Effects:

TG: reduce by 20-50%
HDL-C: modest increase
LDL-C: pure EPA (icosapent ethyl) does not raise LDL; EPA+DHA can slightly raise LDL

Clinical Evidence:

REDUCE-IT trial (icosapent ethyl 4g/day): 25% relative risk reduction in MACE in statin-treated patients with elevated TG (>150 mg/dL) and high CVD risk
STRENGTH trial (EPA+DHA): no CV benefit over placebo

Indication: Severe hypertriglyceridemia (TG >500 mg/dL); CV risk reduction in statin-treated patients with residual hypertriglyceridemia (icosapent ethyl specifically)

8. Newer / Emerging Agents

Drug	Class	Mechanism	Primary Indication
Bempedoic acid	ATP-citrate lyase inhibitor	Blocks cholesterol synthesis upstream of HMG-CoA reductase (hepatocyte-selective; prodrug activated in liver)	Statin-intolerant patients
Inclisiran	siRNA (PCSK9 inhibitor)	RNAi silences PCSK9 mRNA in liver; dosing every 6 months	High LDL, statin intolerant
Evinacumab	Anti-ANGPTL3 mAb	Blocks angiopoietin-like protein 3 -> activates LPL and EL	Homozygous familial hypercholesterolemia
Volanesorsen	Antisense oligonucleotide	Reduces apo C-III synthesis -> reduces TG	Familial chylomicronemia syndrome
Pemafibrate	Selective PPAR-α modulator (SPPARMα)	More selective PPAR-α agonism than fenofibrate	Hypertriglyceridemia

Summary Table: Drug Class vs. Lipid Effects

Drug Class	LDL-C	TG	HDL-C	Primary Use
Statins	↓↓↓	↓	↑	High LDL, CVD risk reduction
Ezetimibe	↓↓	↓	↑	Add-on to statin
PCSK9 inhibitors	↓↓↓↓	↓	↑	FH, high-risk patients
Bile acid sequestrants	↓↓	↑ (caution)	↑	LDL, pregnancy (limited options)
Fibrates	↑ or ↓	↓↓↓	↑↑	Hypertriglyceridemia, low HDL
Niacin	↓	↓↓	↑↑↑	Largely out of favor
Omega-3 fatty acids	neutral/↑	↓↓↓	↑	Hypertriglyceridemia
Bempedoic acid	↓↓	-	-	Statin-intolerant

Clinical Approach to Dyslipidemia

Elevated LDL-C (primary target): Start with statin (intensity based on cardiovascular risk) -> add ezetimibe if goal not achieved -> add PCSK9 inhibitor (evolocumab/alirocumab) for very high-risk patients
Severe hypertriglyceridemia (TG >500 mg/dL): Fibrate or omega-3 fatty acids first (to prevent pancreatitis)
Low HDL-C: Lifestyle first; fibrates/niacin can raise HDL but CV outcome benefit is not proven beyond statin
Mixed dyslipidemia: Statin + fenofibrate (preferred combination); or statin + omega-3

Fuster and Hurst's The Heart, 15th Edition
Goldman-Cecil Medicine, International Edition
Bradley and Daroff's Neurology in Clinical Practice
Fitzpatrick's Dermatology, 5th Edition

This is a shared conversation. Sign in to Orris to start your own chat.